Cesar Rodriguez, MD

In the closing remarks, Dr. Shambavi Richard reflects on the key themes that emerged throughout the discussion on the evolving role of BCMA-directed therapies in relapsed/refractory multiple myeloma (R/R MM).

The faculty discuss treatment sequencing for a patient with relapsed/refractory multiple myeloma (R/R MM) who has experienced disease progression following prior BCMA-directed therapy.

The faculty discuss treatment selection for a fit patient with relapsed/refractory multiple myeloma (R/R MM) who is eligible for both CAR-T cell therapy and BCMA bispecific antibodies and has access to a certified CAR-T treatment center.

The faculty discuss the management of a patient with relapsed/refractory multiple myeloma (R/R MM) who has received four prior lines of therapy but faces significant logistical barriers to CAR-T treatment because of limited caregiver support and distance from a cellular therapy center.

The final FACE-OFF debate examines whether BCMA bispecific antibodies will retain a meaningful role in the management of relapsed/refractory multiple myeloma (R/R MM) as these therapies continue to move into earlier lines of treatment.

The second FACE-OFF debate explores whether currently available BCMA bispecific antibodies should be considered a therapeutic class or whether meaningful clinical differences exist among individual agents used to treat relapsed/refractory multiple myeloma (R/R MM).

The program transitions to the first FACE-OFF debate, where the faculty discuss whether CAR-T cell therapy or BCMA bispecific antibodies should be prioritized as BCMA-directed therapies move into earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).

Following the MAJESTEC-3 presentation, the faculty discuss how the trial findings may influence the evolving treatment landscape for relapsed/refractory multiple myeloma (R/R MM).

Dr. Harsh Parmar presents results from the phase 3 MAJESTEC-3 trial evaluating the combination of teclistamab and daratumumab versus standard daratumumab-based regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who had received one to three prior lines of therapy.

Following the presentation of the real-world sequencing analysis, the faculty discuss how these findings align with their own clinical experience treating relapsed/refractory multiple myeloma (R/R MM).

Dr. Mansi Shah presents a multinational real-world analysis evaluating how BCMA-directed CAR-T cell therapies and BCMA bispecific antibodies are being used in routine clinical practice for patients with relapsed/refractory multiple myeloma (R/R MM).

Following the presentation of the CARTITUDE-4 trial, the faculty discuss how the study findings may influence treatment strategies for relapsed/refractory multiple myeloma (R/R MM).

Dr. Cesar Rodriguez presents findings from the phase 3 CARTITUDE-4 trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who were refractory to lenalidomide after one to three prior lines of therapy.

Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM).

Dr. Shambavi Richard welcomes viewers to Cancer Network's FACE-OFF, introducing a debate-driven educational program focused on the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM).

Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.

A panel of experts on multiple myeloma discuss dermatologic adverse effects seen in patients receiving talquetamab, including nail toxicities.

Multiple myeloma specialists discuss patient education approaches regarding the management of oral toxicity stemming from talquetamab treatment and outline potential research approaches.

Following a review of oral adverse events, the expert panel discusses how to manage oral toxicities seen in patients with multiple myeloma who are treated with talquetamab.

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.

The panel discusses the safety profile of talquetamab for patients with relapsed/refractory multiple myeloma.

Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.

The expert panel provides an overview of relapsed/refractory multiple myeloma, with a focus on current therapeutic options and unmet needs in the treatment space.

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.